Clinical Trial Update: Selective PDE9 Inhibition With IMR-687 in Adults With Heart Failure With Preserved Ejection Fraction [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating the selective PDE9 inhibitor IMR-687 for heart failure with preserved ejection fraction has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure with Preserved Ejection Fraction

Drugs mentioned

• IMR-687

Snippet

Sponsor: Cardurion Pharmaceuticals, Inc. | Conditions: Heart Failure With Preserved Ejection Fraction | Phase 2 | Status: WITHDRAWN